Metabolic Flexibility to Predict Lifestyle Interventions Outcomes
Recruiting · NCT06329349 · Interventional (participants receive a specific treatment) · Lead sponsor: Charles University, Czech Republic
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Weight loss is a cornerstone of diabetes (T2D) management, yet in clinical practice, its delivery is limited by its perceived burdensome nature and variability in response. Personalization of the interventions to increase their success rate is an unmet clinical need. The proposed project MEPHISTO (Whole body and gut microbiome metabolic flexibility to predict lifestyle intervention outcomes) would aim to identify predictive features related to successful weight loss upon sequential exercise and diet intervention in people living with obesity. To this end, the study aims to conduct a clinical trial where the investigators would implement state-of-the-art physiological phenotyping of metabolic flexibility at the whole-body level and at the level of the gut in persons with obesity before and after exercise and diet + exercise intervention to identify predictive signatures of successful weight loss
Who can take part
Inclusion criteria
- BMI\>30
- age 25-45 years
Exclusion criteria
- active cancer
- diabetes (medical history, fasting glycemia \>7.6 and/or 2hOGTT glycemia \>11.1)
- uncontrolled endocrine diseases
- corticosteroid therapy
- immune-suppressive therapy
- pregnancy
- breastfeeding
Where it is running
3 locations listed.
- University Hospital Kralovske Vinohrady - Prague, Czechia
- Third Medical Faculty,Charles University - Prague, Czechia
- Faculty of Sports Science - Prague, Czechia